Skip to main content
Erschienen in: Infection 6/2022

04.07.2022 | Review

Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infections

verfasst von: Sisi Zhen, Hui Wang, Sizhou Feng

Erschienen in: Infection | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime–avibactam (CAZ–AVI) is a newer combination of β-lactam/β-lactamase inhibitor, with activity against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). The aim of this review is to describe the recent real-world experience of CAZ–AVI for the infections due to MDR-GNB.

Methods

We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. Reference lists were reviewed and synthesized for narrative review.

Results

MDRGNB infections are associated with higher mortality significantly comparing to drug-susceptible bacterial infections. Fortunately, CAZ–AVI shows significant benefits for infections due to KPC or OXA-48 CRE, comparing to colistin, carbapenem, aminoglycoside and other older agents, even in those with immunocompromised status. The efficacy of CAZ–AVI varies in different infection sites due to CRE, which is lower in pneumonia. Early use is associated with improved clinical outcomes. Noteworthy, when adopted as salvage therapy, CAZ–AVI is still superior to other GNB active antibiotics. CAZ–AVI plus aztreonam is recommended as the first line of MBL-CRE infections. However, for infections caused by KPC- and OXA-48-producing isolates, further investigations are needed to demonstrate the benefit of combination therapy. Besides CRE, CAZ-AVI is also active to MDR-PA. However, the development of resistance in CRE and MDR-PA against CAZ–AVI is alarming, and more investigations and studies are needed to prevent, diagnose, and treat infections due to CAZ–AVI-resistant pathogens.

Conclusions

CAZ-AVI appears to be a valuable therapeutic option in MDR-GNB infections. Using CAZ-AVI appropriately to improve efficacy and decrease the emergence of resistance is important.
Literatur
2.
Zurück zum Zitat Grundmann H, Glasner C, Albiger B, Aanensen D, Tomlinson C, Andrasević A, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63. https://doi.org/10.1016/s1473-3099(16)30257-2.CrossRefPubMed Grundmann H, Glasner C, Albiger B, Aanensen D, Tomlinson C, Andrasević A, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63. https://​doi.​org/​10.​1016/​s1473-3099(16)30257-2.CrossRefPubMed
5.
Zurück zum Zitat Weiner L, Webb A, Limbago B, Dudeck M, Patel J, Kallen A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–301. https://doi.org/10.1017/ice.2016.174.CrossRefPubMedCentralPubMed Weiner L, Webb A, Limbago B, Dudeck M, Patel J, Kallen A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–301. https://​doi.​org/​10.​1017/​ice.​2016.​174.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Maraolo A, Corcione S, Grossi A, Signori A, Alicino C, Hussein K, et al. The impact of carbapenem resistance on mortality in patients with klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Therapy. 2021;10(1):541–58. https://doi.org/10.1007/s40121-021-00408-8.CrossRef Maraolo A, Corcione S, Grossi A, Signori A, Alicino C, Hussein K, et al. The impact of carbapenem resistance on mortality in patients with klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Therapy. 2021;10(1):541–58. https://​doi.​org/​10.​1007/​s40121-021-00408-8.CrossRef
16.
Zurück zum Zitat Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076–81. https://doi.org/10.1002/ajh.24489. Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076–81. https://​doi.​org/​10.​1002/​ajh.​24489.
22.
26.
Zurück zum Zitat Almangour T, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N, et al. Ceftazidime–avibactam versus colistin for the treatment of infections due to carbapenem-resistant enterobacterales: a multicenter cohort study. Infect Drug Resistance. 2022;15:211–21. https://doi.org/10.2147/idr.S349004.CrossRef Almangour T, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N, et al. Ceftazidime–avibactam versus colistin for the treatment of infections due to carbapenem-resistant enterobacterales: a multicenter cohort study. Infect Drug Resistance. 2022;15:211–21. https://​doi.​org/​10.​2147/​idr.​S349004.CrossRef
28.
Zurück zum Zitat Castón J, Cano A, Pérez-Camacho I, Aguado J, Carratalá J, Ramasco F, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother. 2022. https://doi.org/10.1093/jac/dkac049.CrossRefPubMed Castón J, Cano A, Pérez-Camacho I, Aguado J, Carratalá J, Ramasco F, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother. 2022. https://​doi.​org/​10.​1093/​jac/​dkac049.CrossRefPubMed
29.
Zurück zum Zitat Shields R, Nguyen M, Chen L, Press E, Potoski B, Marini R, et al. Ceftazidime–avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.00883-17. Shields R, Nguyen M, Chen L, Press E, Potoski B, Marini R, et al. Ceftazidime–avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​00883-17.
33.
Zurück zum Zitat Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A, et al. Ceftazidime–avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients. Antimicrob Agents Chemother. 2020;64. https://doi.org/10.1128/aac.02320-19. Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A, et al. Ceftazidime–avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients. Antimicrob Agents Chemother. 2020;64. https://​doi.​org/​10.​1128/​aac.​02320-19.
34.
Zurück zum Zitat Shen L, Lian C, Zhu B, Yao Y, Yang Q, Zhou J, et al. Klebsiella pneumonia bloodstream infections due to carbapenem-resistant : a single-center retrospective study on risk factors and therapy options. Microbial drug resistance (Larchmont, NY). 2021;27:227–33. https://doi.org/10.1089/mdr.2019.0455.CrossRef Shen L, Lian C, Zhu B, Yao Y, Yang Q, Zhou J, et al. Klebsiella pneumonia bloodstream infections due to carbapenem-resistant : a single-center retrospective study on risk factors and therapy options. Microbial drug resistance (Larchmont, NY). 2021;27:227–33. https://​doi.​org/​10.​1089/​mdr.​2019.​0455.CrossRef
36.
Zurück zum Zitat Ackley R, Roshdy D, Meredith J, Minor S, Anderson W, Capraro G, et al. Enterobacteriaceae meropenem–vaborbactam versus ceftazidime–avibactam for treatment of carbapenem-resistant infections. antimicrob agents chemother. 2020;64. https://doi.org/10.1128/aac.02313-19. Ackley R, Roshdy D, Meredith J, Minor S, Anderson W, Capraro G, et al. Enterobacteriaceae meropenem–vaborbactam versus ceftazidime–avibactam for treatment of carbapenem-resistant infections. antimicrob agents chemother. 2020;64. https://​doi.​org/​10.​1128/​aac.​02313-19.
38.
Zurück zum Zitat Tumbarello M, Trecarichi E, Corona A, De Rosa F, Bassetti M, Mussini C, et al. Efficacy of Ceftazidime–avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68:355–64. https://doi.org/10.1093/cid/ciy492. Tumbarello M, Trecarichi E, Corona A, De Rosa F, Bassetti M, Mussini C, et al. Efficacy of Ceftazidime–avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68:355–64. https://​doi.​org/​10.​1093/​cid/​ciy492.
39.
Zurück zum Zitat Shields R, Nguyen M, Chen L, Press E, Kreiswirth B, Clancy C. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime–avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018;62. https://doi.org/10.1128/aac.02497-17. Shields R, Nguyen M, Chen L, Press E, Kreiswirth B, Clancy C. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime–avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018;62. https://​doi.​org/​10.​1128/​aac.​02497-17.
40.
43.
Zurück zum Zitat Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L, et al. Klebsiella pneumoniaeCeftazidime–avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant in Liver Transplantation Recipients. Infect Drug Resistance. 2021;14:5603–12. https://doi.org/10.2147/idr.S342163.CrossRef Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L, et al. Klebsiella pneumoniaeCeftazidime–avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant in Liver Transplantation Recipients. Infect Drug Resistance. 2021;14:5603–12. https://​doi.​org/​10.​2147/​idr.​S342163.CrossRef
45.
47.
Zurück zum Zitat King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter Study of Outcomes with Ceftazidime–avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.00449-17. King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter Study of Outcomes with Ceftazidime–avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​00449-17.
48.
Zurück zum Zitat Shields R, Potoski B, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8. https://doi.org/10.1093/cid/ciw636. Shields R, Potoski B, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8. https://​doi.​org/​10.​1093/​cid/​ciw636.
49.
Zurück zum Zitat King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Outcomes With Ceftazidime/Avibactam in Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: A Multicenter Study. Open Forum Infectious Diseases. 2016;3. https://doi.org/10.1093/ofid/ofw172.1595. King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Outcomes With Ceftazidime/Avibactam in Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: A Multicenter Study. Open Forum Infectious Diseases. 2016;3. https://​doi.​org/​10.​1093/​ofid/​ofw172.​1595.
51.
Zurück zum Zitat Fiore M, Alfieri A, Di Franco S, Pace M, Simeon V, Ingoglia G, et al. Ceftazidime–avibactam Combination Therapy Compared to Ceftazidime–avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics (Basel, Switzerland). 2020;9. https://doi.org/10.3390/antibiotics9070388. Fiore M, Alfieri A, Di Franco S, Pace M, Simeon V, Ingoglia G, et al. Ceftazidime–avibactam Combination Therapy Compared to Ceftazidime–avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics (Basel, Switzerland). 2020;9. https://​doi.​org/​10.​3390/​antibiotics90703​88.
54.
Zurück zum Zitat Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et al. Ceftazidime–avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime–avibactam in monotherapy in critically Ill patients with carbapenem-resistant klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Therapy. 2021;10:1699–713. https://doi.org/10.1007/s40121-021-00479-7.CrossRef Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et al. Ceftazidime–avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime–avibactam in monotherapy in critically Ill patients with carbapenem-resistant klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Therapy. 2021;10:1699–713. https://​doi.​org/​10.​1007/​s40121-021-00479-7.CrossRef
55.
Zurück zum Zitat Shaw E, Rombauts A, Tubau F, Padullés A, Càmara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73:1104–6. https://doi.org/10.1093/jac/dkx496.CrossRefPubMed Shaw E, Rombauts A, Tubau F, Padullés A, Càmara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73:1104–6. https://​doi.​org/​10.​1093/​jac/​dkx496.CrossRefPubMed
56.
Zurück zum Zitat Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime–avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.01008-17. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime–avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​01008-17.
57.
Zurück zum Zitat Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, Flores-Treviño S, Kim H, Perez-Alba E. Aztreonam plus ceftazidime–avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? J Global Antimicrobial Resistance. 2020;23:417–9. https://doi.org/10.1016/j.jgar.2020.10.019. Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, Flores-Treviño S, Kim H, Perez-Alba E. Aztreonam plus ceftazidime–avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? J Global Antimicrobial Resistance. 2020;23:417–9. https://​doi.​org/​10.​1016/​j.​jgar.​2020.​10.​019.
59.
Zurück zum Zitat Yasmin M, Fouts D, Jacobs M, Haydar H, Marshall S, White R, et al. Monitoring Ceftazidime–avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;711095–8. https://doi.org/10.1093/cid/ciz1155. Yasmin M, Fouts D, Jacobs M, Haydar H, Marshall S, White R, et al. Monitoring Ceftazidime–avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;711095–8. https://​doi.​org/​10.​1093/​cid/​ciz1155.
60.
Zurück zum Zitat Sieswerda E, van den Brand M, van den Berg R, Sträter J, Schouls L, van Dijk K, et al. Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam. J Antimicrob Chemother. 2020;75:773–5. https://doi.org/10.1093/jac/dkz495.CrossRefPubMed Sieswerda E, van den Brand M, van den Berg R, Sträter J, Schouls L, van Dijk K, et al. Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam. J Antimicrob Chemother. 2020;75:773–5. https://​doi.​org/​10.​1093/​jac/​dkz495.CrossRefPubMed
64.
Zurück zum Zitat Jorgensen S, Trinh T, Zasowski E, Lagnf A, Bhatia S, Melvin S, et al. Real-World Experience With Ceftazidime–avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open forum infectious diseases. 2019;6:ofz522. https://doi.org/10.1093/ofid/ofz522. Jorgensen S, Trinh T, Zasowski E, Lagnf A, Bhatia S, Melvin S, et al. Real-World Experience With Ceftazidime–avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open forum infectious diseases. 2019;6:ofz522. https://​doi.​org/​10.​1093/​ofid/​ofz522.
65.
Zurück zum Zitat Guimarães T, Nouér S, Martins R, Perdigão Neto L, Martins W, Narciso Barbosa A, et al. EnterobacterialesCeftazidime–avibactam as Salvage Therapy for Infections Caused by Coresistant to Carbapenems and Polymyxins. Antimicrob Agents Chemother. 2019;63. https://doi.org/10.1128/aac.00528-19. Guimarães T, Nouér S, Martins R, Perdigão Neto L, Martins W, Narciso Barbosa A, et al. EnterobacterialesCeftazidime–avibactam as Salvage Therapy for Infections Caused by Coresistant to Carbapenems and Polymyxins. Antimicrob Agents Chemother. 2019;63. https://​doi.​org/​10.​1128/​aac.​00528-19.
68.
Zurück zum Zitat Shields R, Chen L, Cheng S, Chavda K, Press E, Snyder A, et al. blaEmergence of Ceftazidime–avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.02097-16. Shields R, Chen L, Cheng S, Chavda K, Press E, Snyder A, et al. blaEmergence of Ceftazidime–avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​02097-16.
69.
Zurück zum Zitat Shields R, Nguyen M, Press E, Chen L, Kreiswirth B, Clancy C. Klebsiella pneumonia emergence of ceftazidime–avibactam resistance and restoration of carbapenem susceptibility in carbapenemase-producing: a case report and review of literature. Open forum infectious diseases. 2017;4:ofx101. https://doi.org/10.1093/ofid/ofx101. Shields R, Nguyen M, Press E, Chen L, Kreiswirth B, Clancy C. Klebsiella pneumonia emergence of ceftazidime–avibactam resistance and restoration of carbapenem susceptibility in carbapenemase-producing: a case report and review of literature. Open forum infectious diseases. 2017;4:ofx101. https://​doi.​org/​10.​1093/​ofid/​ofx101.
70.
Zurück zum Zitat Giddins M, Macesic N, Annavajhala M, Stump S, Khan S, McConville T, et al. blaSuccessive emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in -harboring klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62. https://doi.org/10.1128/aac.02101-17. Giddins M, Macesic N, Annavajhala M, Stump S, Khan S, McConville T, et al. blaSuccessive emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in -harboring klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62. https://​doi.​org/​10.​1128/​aac.​02101-17.
71.
72.
Zurück zum Zitat Athans V, Neuner E, Hassouna H, Richter S, Keller G, Castanheira M, et al. Klebsiella pneumoniaeMeropenem–vaborbactam as Salvage Therapy for Ceftazidime–avibactam-Resistant Bacteremia and Abscess in a Liver Transplant Recipient. Antimicrob Agents Chemother. 2019;63. https://doi.org/10.1128/aac.01551-18. Athans V, Neuner E, Hassouna H, Richter S, Keller G, Castanheira M, et al. Klebsiella pneumoniaeMeropenem–vaborbactam as Salvage Therapy for Ceftazidime–avibactam-Resistant Bacteremia and Abscess in a Liver Transplant Recipient. Antimicrob Agents Chemother. 2019;63. https://​doi.​org/​10.​1128/​aac.​01551-18.
76.
Zurück zum Zitat Venditti C, Nisii C, D’Arezzo S, Vulcano A, Capone A, Antonini M, et al. blaMolecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime–avibactam resistance in -harboring. Infect Drug Resistance. 2019;12:1935–40. https://doi.org/10.2147/idr.S207993.CrossRef Venditti C, Nisii C, D’Arezzo S, Vulcano A, Capone A, Antonini M, et al. blaMolecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime–avibactam resistance in -harboring. Infect Drug Resistance. 2019;12:1935–40. https://​doi.​org/​10.​2147/​idr.​S207993.CrossRef
78.
Zurück zum Zitat Galani I, Karaiskos I, Souli M, Papoutsaki V, Galani L, Gkoufa A, et al. Klebsiella pneumoniaeOutbreak of KPC-2-producing endowed with ceftazidime–avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25. https://doi.org/10.2807/1560-7917.Es.2020.25.3.2000028. Galani I, Karaiskos I, Souli M, Papoutsaki V, Galani L, Gkoufa A, et al. Klebsiella pneumoniaeOutbreak of KPC-2-producing endowed with ceftazidime–avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25. https://​doi.​org/​10.​2807/​1560-7917.​Es.​2020.​25.​3.​2000028.
79.
Zurück zum Zitat Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, et al. Emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Euro J Clin Microbiol Infect Dis. 2021;40(1):219–24. https://doi.org/10.1007/s10096-020-04000-9.CrossRef Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, et al. Emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Euro J Clin Microbiol Infect Dis. 2021;40(1):219–24. https://​doi.​org/​10.​1007/​s10096-020-04000-9.CrossRef
80.
Zurück zum Zitat Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón J, Gracia-Ahufinger I, Pérez-Nadales E, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J Global Antimicrobial Resistance. 2020;22:9–12. https://doi.org/10.1016/j.jgar.2019.11.007.CrossRef Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón J, Gracia-Ahufinger I, Pérez-Nadales E, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J Global Antimicrobial Resistance. 2020;22:9–12. https://​doi.​org/​10.​1016/​j.​jgar.​2019.​11.​007.CrossRef
84.
91.
94.
Zurück zum Zitat Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, et al. Resistance to Ceftazidime–avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.00989-17. Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, et al. Resistance to Ceftazidime–avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​00989-17.
95.
Zurück zum Zitat Shields R, Clancy C, Hao B, Chen L, Press E, Iovine N, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime–avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59:5793–7. https://doi.org/10.1128/aac.00548-15. Shields R, Clancy C, Hao B, Chen L, Press E, Iovine N, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime–avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59:5793–7. https://​doi.​org/​10.​1128/​aac.​00548-15.
96.
Zurück zum Zitat Zhang Y, Kashikar A, Brown C, Denys G, Bush K. In VitroUnusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.00389-17. Zhang Y, Kashikar A, Brown C, Denys G, Bush K. In VitroUnusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​00389-17.
97.
Zurück zum Zitat Fontana C, Favaro M, Campogiani L, Malagnino V, Minelli S, Bossa M, et al. Klebsiella pneumoniaeCeftazidime/Avibactam-Resistant subsp. Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance. Microorganisms. 2021;9. https://doi.org/10.3390/microorganisms9112356. Fontana C, Favaro M, Campogiani L, Malagnino V, Minelli S, Bossa M, et al. Klebsiella pneumoniaeCeftazidime/Avibactam-Resistant subsp. Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance. Microorganisms. 2021;9. https://​doi.​org/​10.​3390/​microorganisms91​12356.
99.
100.
Zurück zum Zitat Gaibani P, Re M, Campoli C, Viale P, Ambretti S. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26:516.e1-.e4. https://doi.org/10.1016/j.cmi.2019.11.011. Gaibani P, Re M, Campoli C, Viale P, Ambretti S. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26:516.e1-.e4. https://​doi.​org/​10.​1016/​j.​cmi.​2019.​11.​011.
103.
Zurück zum Zitat Vena A, Giacobbe D, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. EnterobacteralesClinical Experience with Ceftazidime–avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant. Antibiotics (Basel, Switzerland). 2020;9. https://doi.org/10.3390/antibiotics9020071. Vena A, Giacobbe D, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. EnterobacteralesClinical Experience with Ceftazidime–avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant. Antibiotics (Basel, Switzerland). 2020;9. https://​doi.​org/​10.​3390/​antibiotics90200​71.
104.
106.
Zurück zum Zitat Meschiari M, Franconi I, Bacca E, Bianco V, Orlando G, Cuomo G, et al. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection. 2021;49:549–53. https://doi.org/10.1007/s15010-020-01539-9.CrossRefPubMed Meschiari M, Franconi I, Bacca E, Bianco V, Orlando G, Cuomo G, et al. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection. 2021;49:549–53. https://​doi.​org/​10.​1007/​s15010-020-01539-9.CrossRefPubMed
108.
Zurück zum Zitat Gatti M, Virgili G, Cojutti P, Gaibani P, Conti M, Sturiale C, et al. Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–avibactam-Based Regimens: A Report of Two Cases. Microorganisms. 2022;10. https://doi.org/10.3390/microorganisms10010154. Gatti M, Virgili G, Cojutti P, Gaibani P, Conti M, Sturiale C, et al. Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–avibactam-Based Regimens: A Report of Two Cases. Microorganisms. 2022;10. https://​doi.​org/​10.​3390/​microorganisms10​010154.
109.
Zurück zum Zitat Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha J, et al. Selection of AmpC β-Lactamase variants and metallo-β-lactamases leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance during treatment of MDR/XDR pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2022;66(2): e0206721. https://doi.org/10.1128/aac.02067-21.CrossRefPubMed Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha J, et al. Selection of AmpC β-Lactamase variants and metallo-β-lactamases leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance during treatment of MDR/XDR pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2022;66(2): e0206721. https://​doi.​org/​10.​1128/​aac.​02067-21.CrossRefPubMed
110.
111.
Zurück zum Zitat Fraile-Ribot P, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez J, et al. In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/aac.01117-17. Fraile-Ribot P, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez J, et al. In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61. https://​doi.​org/​10.​1128/​aac.​01117-17.
112.
Zurück zum Zitat Boulant T, Jousset A, Bonnin R, Barrail-Tran A, Borgel A, Oueslati S, et al. Pseudomonas aeruginosaA 2.5-years within-patient evolution of a with acquisition of ceftolozane-tazobactam and ceftazidime–avibactam resistance upon treatment. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/aac.01637-19. Boulant T, Jousset A, Bonnin R, Barrail-Tran A, Borgel A, Oueslati S, et al. Pseudomonas aeruginosaA 2.5-years within-patient evolution of a with acquisition of ceftolozane-tazobactam and ceftazidime–avibactam resistance upon treatment. Antimicrob Agents Chemother. 2019. https://​doi.​org/​10.​1128/​aac.​01637-19.
113.
Zurück zum Zitat Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro B, Cabot G, Vázquez-Ucha J, Rodríguez-Iglesias M, et al. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2021;76:91–100. https://doi.org/10.1093/jac/dkaa396.CrossRefPubMed Arca-Suárez J, Lasarte-Monterrubio C, Rodiño-Janeiro B, Cabot G, Vázquez-Ucha J, Rodríguez-Iglesias M, et al. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2021;76:91–100. https://​doi.​org/​10.​1093/​jac/​dkaa396.CrossRefPubMed
114.
Zurück zum Zitat Horcajada J, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev. 2019;32. https://doi.org/10.1128/cmr.00031-19. Horcajada J, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev. 2019;32. https://​doi.​org/​10.​1128/​cmr.​00031-19.
Metadaten
Titel
Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infections
verfasst von
Sisi Zhen
Hui Wang
Sizhou Feng
Publikationsdatum
04.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2022
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01876-x

Weitere Artikel der Ausgabe 6/2022

Infection 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.